Study finds no benefit of anti-malaria drug hydroxychloroquine promoted by Trump
Drug appeared to neither help nor harm COVID-19 patients
By 
THE LARGEST STUDY to date of hydroxychloroquine, the antimalarial drug touted by President Trump as a potential “game-changer” in the treatment of coronavirus, found no evidence of a benefit in treating severely ill COVID-19 patients. The study, published Thursday in the New England Journal of Medicine, looked at the drug’s effect on COVID-19 patients admitted(...)